Annovis Bio (ANVS) is developing a drug that improves cognition and motor function among patients with Alzheimer’s and Parkinson’s Diseases. Founder and CEO, Maria Maccecchini, discusses what separates the Annovis Bio treatment from other therapies. Annovis Bio’s stock hit an all-time high on May 25th and Maccecchini has a very positive outlook for the future of the drug and company. Tune in to find out more.
The Watch List
11 Jun 2021
SHARE
Market On Close
05 Apr 2022
Trading 360
18 Apr 2022
The Watch List
28 Apr 2022
Trading 360
11 Apr 2022
The Watch List
20 Apr 2022
The Watch List
13 May 2022